Genomic Biomarkers Market expected to reach USD 36.127 billion by 2030

Genomic Biomarkers Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the genomic biomarkers market will expand from USD 22.631 billion in 2025 to USD 36.127 billion in 2030 at a CAGR of 9.81% during the forecast period.

The rise in the cases of chronic ailments such as cardiovascular diseases, cancer, and neurological syndromes, along with the increased investment in the healthcare sector for the development of advanced diagnostic equipment like genomic biomarkers, is promoting the market.

The increase in regulatory approvals for the integration of these biomarkers in designing precision medicines, followed by these genomic biomarker applications in enabling research and development due to the detection of the responsible patient population, are also significant drivers in this market. The growing advancement and product innovation by market players through collaboration and FDA approval are also fuelling the market growth. Moreover, the rise in the development of oncology precision medicine involving clinical trials is also promoting the requirement for advanced genomic biomarkers globally.

Genomic Biomarkers Market Report Highlights

• The predictive biomarkers segment is estimated to expand to hold a greater market share by 2030 in the form segment. The segment is increasing due to its application in companion diagnostics and for the selection of immediate treatment. Additionally, the growing factor of rise in utilization of clinical trials for the development of novel drugs, along with improvement in bioinformatics and genomics, along with growing AI integration for proactive interventions, is also boosting the segment.
• The neurological diseases segment is the fastest-growing segment in the indication of the global genomic biomarkers market, due to its rise in neurological diseases such as Alzheimer’s globally, which is leading to the requirement for blood-based assays for the decrease in invasion of disease. The rise in research and insights on the genetics of this disease is also paving the way for supporting early intervention and designing targeted treatment of this disease, in turn, boosting the market.
• The hospital is the dominating segment in the genomic biomarkers market in the end-use segment during the projected period. This is due to the presence of in-house laboratory facilities, along with consolidating the purchases of these genomic markers. Further, the increase in government spending on clinical testing and the rise in focus for quick research and development in the diagnosis of diseases like cardiovascular disease, neurological disorders, and cancers, which will promote advancement in genomic biomarkers, along with their adoption in hospitals.
• North America is expected to hold the largest genomic biomarkers market share on account of the robust healthcare infrastructure and the presence of robust laboratory networks. Additionally, the presence of FDA guidance with high clinical trials conducted in the region is due to the presence of major market players in the region. This development is boosting the research and development in genomics to promote accurate diagnosis in the region.

Report Coverage:

Report Metric	Details
Genomic Biomarkers Market Size in 2025	US$22.631 billion
Genomic Biomarkers Market Size in 2030	US$36.127 billion
Growth Rate	CAGR of 9.81%
Drivers	Increasing Prevalence of Chronic and Lifestyle Diseases Growing Advancements in Technologies and Innovations
Restraints	High Costs of Development and Capital Investments Regulatory Complexities
Segmentation	Type Indication End User Geography
List of Major Companies in Genomic Biomarkers Market	Thermo Fisher Scientific Inc Illumina, Inc. REVEAL GENOMICS, S.L. Guardant Health Complete Genomics Incorporated

Genomic Biomarkers Market Growth Drivers and Restraints

Growth Drivers:

• Increasing Prevalence of Chronic and Lifestyle Diseases: The growing prevalence of diseases such as cardiovascular issues, cancers, and neurological disorders, and other lifestyle diseases, is leading to an increase in demand for genomic biomarkers. These biomarkers are essential for early identification, prognosis, and management while also supporting personalized treatment and a decrease in lifestyle disorder-related mortality.
• Growing Advancements in Technologies and Innovations: The rise in innovation in proteomics, AI/bioinformatics, and next-generation sequencing (NGS), which are utilized in analysis for oncology. These advancements in technology are boosting the biomarkers that are utilized in the enhancement of diagnostics and drug targets.

Restraints:

• High Costs of Development and Capital Investments: The discovery, testing, and commercialization of genomic biomarkers demand substantial investment, which could lead to limitations in smaller players’ entry into the market.
• Regulatory Complexities: The growing, stringent framework and complexity, for example FDA biomarker qualification program, along with the lack of sample collection and data interpretation, are leading to hurdles in the growth of the market.

Genomic Biomarkers Market Key Development

• Regulatory Approval: In May 2025, Illumina announced the approval of Japan for TruSight Oncology (TSO) Comprehensive test which provides comprehensive genomic profiling (CGP).
• Product Launch: In March 2025, the LuNGS Alliance, which is under the Cancer Research and Statistics Foundation and is also supported by AstraZeneca, Roche, and Pfizer, announced the launch of free lung cancer NGS biomarker testing across India. It will utilize the TARGET First Solid biomarkers, which are supported with FDA/NCCN-approved therapies.

Genomic Biomarkers Market Segmentation

Knowledge Sourcing Intelligence has segmented the genomic biomarkers market based on type, indication, end-user, and region:

Genomic Biomarkers Market, By Type

• Predictive Biomarkers
• Prognostic Biomarkers

Genomic Biomarkers Market, By Indication

• Oncology
• Cardiovascular diseases
• Neurological diseases
• Renal Disorders
• Others

Genomic Biomarkers Market, By End-User

• Hospitals
• Diagnostic Centers
• Others

Genomic Biomarkers Market, By Region

• North America
  • USA
  • Canada
  • Mexico
• South America
  • Brazil
  • Argentina
  • Others
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Others
• Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Indonesia
  • Thailand
  • Others

Genomic Biomarkers Market Key Players

• Almac Group
• Bio-Rad Laboratories Inc.
• Eurofins Scientific
• Myriad Genetics Inc
• QIAGEN
• Thermo Fisher Scientific Inc
• Illumina, Inc.
• REVEAL GENOMICS, S.L.
• Guardant Health
• Complete Genomics Incorporated